ALB and non-small cell lung carcinoma: The combination of sintilimab with albumin-bound paclitaxel plus cisplatin for stage IB–IIIB NSCLC treatment demonstrates favorable clinical efficacy and safety and achieves significant improvement in quality of life and exercise tolerance, thus worthy of clinical promotion and application.